Marshall Wace LLP Invests $562,000 in Mesoblast Limited (NASDAQ:MESO)

Marshall Wace LLP bought a new position in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 82,576 shares of the company's stock, valued at approximately $562,000. Marshall Wace LLP owned 0.07% of Mesoblast as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company's stock worth $34,000 after purchasing an additional 1,663 shares during the period. Perkins Coie Trust Co purchased a new stake in shares of Mesoblast in the 2nd quarter worth about $68,000. Pine Valley Investments Ltd Liability Co bought a new position in shares of Mesoblast in the 2nd quarter worth about $80,000. Rathbones Group PLC purchased a new position in Mesoblast during the 2nd quarter valued at about $95,000. Finally, Chapin Davis Inc. lifted its position in Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock valued at $102,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 1.43% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on MESO. Piper Sandler raised shares of Mesoblast from a "neutral" rating to an "overweight" rating and raised their target price for the company from $4.00 to $11.00 in a research note on Tuesday, July 23rd. Maxim Group upgraded Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. Jefferies Financial Group raised Mesoblast from a "hold" rating to a "buy" rating in a report on Thursday, August 29th. Cantor Fitzgerald restated an "overweight" rating on shares of Mesoblast in a report on Thursday, August 29th. Finally, StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.50.

Mesoblast Stock Up 1.5 %

MESO stock traded up $0.14 during midday trading on Thursday, hitting $9.33. The company's stock had a trading volume of 89,393 shares, compared to its average volume of 843,425. The company has a market cap of $1.07 billion, a PE ratio of -8.21 and a beta of 3.47. The firm's 50-day moving average is $6.91 and its 200-day moving average is $6.85. Mesoblast Limited has a 12 month low of $1.61 and a 12 month high of $11.05. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.